Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 16, pp. 4268-4279
Open Access | Times Cited: 167

Showing 1-25 of 167 citing articles:

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Chang Yang, Bairong Xia, Zhao-Cong Zhang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 237
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 323-339
Open Access | Times Cited: 219
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 473-487
Closed Access | Times Cited: 208
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud, Antoîne Italiano
Cancers (2020) Vol. 12, Iss. 6, pp. 1502-1502
Open Access | Times Cited: 180
Immunomodulation by targeted anticancer agents
Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, et al.
Cancer Cell (2020) Vol. 39, Iss. 3, pp. 310-345
Open Access | Times Cited: 179
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Somayeh Vafaei, Angelina Olegovna Zekiy, Ramadhan Ado Khanamir, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 160
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 112
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Binbin Cheng, Wei Pan, Yi Xing, et al.
European Journal of Medicinal Chemistry (2022) Vol. 230, pp. 114109-114109
Closed Access | Times Cited: 84
Heterogeneity and treatment landscape of ovarian carcinoma
Ana Veneziani, Eduardo González-Ochoa, Husam Alqaisi, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 820-842
Closed Access | Times Cited: 61
Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
Andrei Havași, Simona Căinap, Ana Teodora Havasi, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 544-544
Open Access | Times Cited: 48
The complementarity of DDR, nucleic acids and anti-tumour immunity
Anand Kornepati, Cody M. Rogers, Patrick Sung, et al.
Nature (2023) Vol. 619, Iss. 7970, pp. 475-486
Closed Access | Times Cited: 46
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Olivia Le Saux, Isabelle Ray‐Coquard, Sana Intidhar Labidi‐Galy
Seminars in Cancer Biology (2020) Vol. 77, pp. 127-143
Open Access | Times Cited: 97
Interfaces between cellular responses to DNA damage and cancer immunotherapy
Domenic Pilger, Leonard W. Seymour, Stephen P. Jackson
Genes & Development (2021) Vol. 35, Iss. 9-10, pp. 602-618
Open Access | Times Cited: 80
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Michela Chiappa, Federica Guffanti, Francesco Bertoni, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100744-100744
Closed Access | Times Cited: 74
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 33, pp. 3671-3681
Open Access | Times Cited: 66
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Domenica Lorusso, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4438-4438
Open Access | Times Cited: 57
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Congqi Shi, Kaiyu Qin, Anqi Lin, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 41
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Stefanie Seitz, Tobias Dreyer, Christoph Stange, et al.
British Journal of Cancer (2022) Vol. 126, Iss. 10, pp. 1470-1480
Open Access | Times Cited: 40
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Iva Truxová, David Cibula, Radek Špíšek, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e005968-e005968
Open Access | Times Cited: 37
PARP Inhibitors in Breast and Ovarian Cancer
Samuel Sherng Young Wang, Yeo Ee Jie, Sim Wey Cheng, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2357-2357
Open Access | Times Cited: 26
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance
Petar-Bogomil Kanev, Aleksandar Atemin, Stoyno Stoynov, et al.
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 2-18
Open Access | Times Cited: 22
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Gilles Freyer, Anne Floquet, Olivier Trédan, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes
Amin Ullah, Yongxiu Chen, Rajeev K. Singla, et al.
Pharmacological Research (2024) Vol. 204, pp. 107213-107213
Open Access | Times Cited: 11
The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities
Bianca Garlisi, Sylvia Lauks, Caroline Aitken, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3826-3844
Open Access | Times Cited: 11
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Eleonora Ghisoni, Matteo Morotti, Apostolos Sarivalasis, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top